Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

Singh, Sonal; Chang, Hsien-Yen; Richards, Thomas M; Weiner, Jonathan P; Clark, Jeanne M; Segal, Jodi B
JAMA internal medicine; 2013 Apr 8;173(7):534-9. PMID: 23440284
Department of Medicine, The Johns Hopkins University School of Medicine and Public Health, Baltimore,MD 21287, USA.


Acute pancreatitis has significant morbidity and mortality. Previous studies have raised the possibility that glucagonlike peptide 1 (GLP-1)-based therapies, including a GLP-1 mimetic (exenatide) and a dipeptidyl peptidase 4 inhibitor (sitagliptin phosphate), may increase the risk of acute pancreatitis.